查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401997

2030 年转录组学市场预测：按组件、技术、应用、最终用户和地区进行的全球分析

Transcriptomics Market Forecasts to 2030 - Global Analysis By Component (Instruments, Services, Consumables, Software, Reagents and Other Components), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球转录组学市场规模为 74 亿美元，预计到 2030 年将达到 135 亿美元，预测期内复合年增长率为 9.0%。

对生物体总 RNA 转录本的研究称为转录组学，它提供有关基因表现模式、调控系统和细胞功能的宝贵资讯。转录组学市场包括大量研究人员，旨在研究和解释生物体的整个转录组，以帮助研究人员更好地了解基因在不同情况下如何被激活或抑制，其中包括工具和技术。转录组学可识别疾病特异性基因表现模式和医学中的潜在治疗靶点，从而实现准确的诊断和个人化的治疗策略。

2021 年7 月发表在《免疫学前沿》杂誌上的“高密度血液转录组学揭示了住院个体中SARS-CoV-2 感染的精确免疫特征”。根据题为“免疫特征的高精度免疫特征”的研究论文，这项研究发现，条码的序列完美匹配率平均为97.02%，平均质量得分为35.59±0.07，表明序列测定的，表明测序完成了。

对个人化医疗的兴趣日益浓厚

转录组学对于这种范式转变至关重要，因为它可以深入了解每个个体的基因表现模式。转录组分析是精准医学的关键组成部分，能够识别与疾病相关的特定 RNA 分子和基因特征。有了这些资讯，就可以根据每个患者的分子特征量身定制医疗干预措施，从而获得更准确的诊断、预后和治疗策略。此外，转录组学识别基因表现细微变化的能力可以帮助开发量身定制的治疗方法、减少副作用并提高治疗效果。

初期成本高

对于研究机构和实验室来说，获得最先进的设备、专用试剂和运算资源需要付出庞大的财务成本。转录组技术的取得受到这种价格障碍的限制，特别是对于资源有限的小型研究机构而言。转录组分析很复杂，需要复杂的工具和熟练的工人。然而，转录组在科学界的民主化可能会阻碍一些研究人员和机构将转录组纳入他们的研究计画。

技术进步

RNA序列测定(RNA-Seq) 等高通量序列测定方法的不断进步推动了转录组分析准确性、可扩展性和可负担性的提高。大规模转录组资料集产生了有价值的见解，而日益复杂的生物资讯工具和计算技术的发展进一步增强了这些见解。此外，与蛋白质组学和基因组学等其他体学技术的整合将使人们能够更全面地了解生物过程。

标准化和规范化问题

由于资料分析、报告和样品製备过程缺乏标准化而导致的变异性阻碍了比较转录组分析结果的信心。不同的实验方案和资料处理方法造成的差异降低了结果的有效性，并使建立普遍认可的基准变得更加困难。当结合多个研究计划的资料或与不同大学合作时，这个问题变得非常明显。为了提高转录组学研究的可靠性，需要解决标准化和规范化问题，并需要共同努力创建联合计划来建立标准化协议、品管程序和最佳实践。

新冠肺炎 (COVID-19) 影响：

转录组研究使基因表现模式、识别潜在的治疗标靶以及解释对病毒的免疫反应成为可能。疫情带来了挑战，包括供应链中断，阻碍了转录组学研究所需消耗品和试剂的供应。转录组学研究的重点也可能受到资金和研究重点变化的影响。

次世代定序（NGS）细分市场预计将在预测期内成为最大的细分市场

次世代定序(NGS) 彻底改变了高通量 RNA 分析，因此占据了最大的市场占有率。转录组学研究正在经历一场 NGS 技术的革命，例如 RNA定序(RNA-Seq)，它可以对所实现的转录组进行同步、彻底的研究。此外，快速且准确地平行化数百万个RNA分子序列的能力使我们能够解释基因表现的复杂模式，发现新的转录本，并提供对选择性剪接事件的洞察。研究人员在这方面的能力已经得到提高。

预计药物研发领域在预测期内将出现最高的复合年增长率。

药物研究和开发的进步预示着药物研发发现领域的盈利扩张。透过发现疾病背后的复杂分子途径，转录组学提供了对基因表现模式的完整理解。这些资讯使研究人员能够识别与特定疾病相关的基因和途径，有助于识别和检验药物研发中的目标。此外，转录组分析，特别是使用 RNA定序(RNA-Seq) 等技术，可以促进药物反应、生物标记发现和安全性评估。

占有率最大的地区：

由于支持加大投资、技术进步和科学研究的综合因素，亚太地区占据了最大份额。由于中国、印度、日本和韩国等国家越来越重视基因组学和精准医学，因此对转录组技术的需求越来越大。此外，才华横溢的研究人员的可用性以及对转录组学在环境科学、农业和医学等各个行业的潜在应用的认识不断增强也有助于市场的扩张。

复合年增长率最高的地区：

由于对精准医学、基因组学和合作研究计划的投资增加，预计欧洲地区将实现盈利成长。学术机构、研究机构和政府当局的大力支持促进了先进转录组技术和创新的采用。此外，欧洲生物技术和製药业正在积极将转录组学用于药物研发发现和市场开拓，这正在推动该地区的市场成长。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球转录组市场：依组成部分

  • 介绍
  • 装置
  • 服务
  • 消耗品
  • 软体
  • 试剂
  • 其他组件

第六章全球转录组市场：依技术分类

  • 介绍
  • 次世代定序（NGS）
  • 微阵列
  • 即时定量聚合酶炼式反应 (Q-PCR)
  • 定序技术
  • 聚合酶炼式反应 (PCR)
  • Sanger
  • 其他技术

第七章全球转录组市场：依应用分类

  • 介绍
  • 临床诊断
  • 药物研发
  • 诊断和疾病分析
  • 毒理基因组学
  • 其他用途

第八章全球转录组市场：依最终使用者分类

  • 介绍
  • 製药和生物技术公司
  • 政府机构及学术中心
  • 受託研究机构
  • 医院
  • 其他最终用户

第九章全球转录组市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • 10X Genomics
  • Agilent Technologies Inc.
  • BGI Genomics
  • Bio-Rad Laboratories
  • Dovetail Genomics
  • F-Hoffmann La-Roche
  • Fluidigm Corporation
  • GE Healthcare Dharmacon Inc
  • General Electric Company
  • Illuminia Inc.
  • Merck & Co. Inc
  • Natera Inc
  • Pacific Biosciences of California Inc.
  • PerkinElmer Inc.
  • Promega Corporation
  • QiagenInc
  • Takara Bio Inc.
  • Thermofisher Scientific
Product Code: SMRC24517

According to Stratistics MRC, the Global Transcriptomics Market is accounted for $7.4 billion in 2023 and is expected to reach $13.5 billion by 2030 growing at a CAGR of 9.0% during the forecast period. The study of an organism's entire range of RNA transcripts is known as transcriptomics, and it offers valuable information about patterns of gene expression, regulatory systems, and cellular functions. In order to help researchers better understand how genes are activated or inhibited under various circumstances, the transcriptomics market includes tools and technologies that are intended to study and interpret an organism's whole transcriptome. Transcriptomics identifies disease-specific gene expression patterns and possible therapeutic targets in healthcare, enabling accurate diagnosis and individualized therapy strategies.

According to a research article titled "High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals" published in Frontiers in Immunology Journal in July 2021, the study had an average of 97.02% of sequences with perfect matching barcodes and a mean quality score of 35.59 ± 0.07, indicated that the sequencing was performed to a high level with low error.

Market Dynamics:

Driver:

Growing focus on personalized medicine

Because transcriptomics offers deep insights into each person's personal gene expression patterns, it is essential to this paradigm shift. Transcriptomic analysis, a key element of precision medicine, makes it possible to identify certain RNA molecules and gene signatures linked to diseases. With the use of this information, medical interventions can be specifically tailored to the molecular traits of each patient, resulting in more precise diagnoses, prognoses, and treatment strategies. Moreover, transcriptomics' capacity to identify small changes in gene expression aids in the creation of tailored treatments, reducing side effects, and increasing therapeutic effectiveness.

Restraint:

High initial costs

For research organizations and laboratories, acquiring cutting-edge equipment, specialty reagents, and computational resources comes at a substantial financial cost. Access to transcriptome technologies is restricted by this price barrier, especially for smaller research organizations with limited resources. The cost issue is made worse by the complex nature of the transcriptome analysis, which calls for sophisticated tools as well as skilled workers. However, the democratization of transcriptomics among the scientific community may be hampered for some researchers and institutions when attempting to include it in their research programs.

Opportunity:

Technological advancements

Improved accuracy, scalability, and affordability in transcriptomic analysis have resulted from ongoing advancements in high-throughput sequencing methods, such as RNA sequencing (RNA-Seq). Large-scale transcriptomic data sets can yield valuable insights that are further enhanced by the development of increasingly complex bioinformatics tools and computational techniques. Moreover, a more comprehensive understanding of biological processes is made possible by integration with other omics technologies, such as proteomics and genomics.

Threat:

Standardization and normalization issues

Reliability in comparing transcriptomic results is hampered by variability introduced by non-standardized processes for data analysis, reporting, and sample preparation. Inconsistencies originate from different experimental protocols and data processing methods, which reduce the validity of results and make it more difficult to establish generally recognized benchmarks. When combining data from several research projects or working with different universities, this problem is very apparent. Enhancing the reliability of transcriptome studies requires addressing standardization and normalization issues, requiring coordinated efforts to create standardized protocols, quality control procedures, and cooperative projects that establish best practices.

COVID-19 Impact:

Deciphering gene expression patterns, identifying possible treatment targets, and explaining immunological responses to the virus have all been made feasible, in large part due to transcriptomics. The pandemic has brought out difficulties, including supply chain interruptions that impede the availability of consumables and reagents necessary for transcriptomic studies. Transcriptomics study emphasis may also have been impacted by changes in funding and research priorities.

The next-generation sequencing (NGS) segment is expected to be the largest during the forecast period

Because Next-Generation Sequencing (NGS) has revolutionized high-throughput RNA analysis, it accounts for the largest share of the market. Transcriptomic research has experienced a revolution due to NGS technologies like RNA sequencing (RNA-Seq), which allow for the simultaneous and thorough investigation of accomplished transcriptomes. Furthermore, the ability to rapidly and accurately sequence millions of RNA molecules in parallel has improved researchers' ability to interpret intricate patterns of gene expression, discover new transcripts, and provide insight into alternative splicing events.

The drug discovery segment is expected to have the highest CAGR during the forecast period

Because of the advancements in pharmaceutical research and development, the drug discovery segment is predicted to see profitable expansion. Through the discovery of complex molecular pathways underlying diseases, transcriptomics offers a thorough understanding of gene expression patterns. This information helps identify and validate targets in drug discovery by enabling researchers to identify genes and pathways linked to particular illnesses. Moreover, drug reactions, biomarker discovery, and safety evaluation are made easier by transcriptomic analysis, especially when using technologies such as RNA sequencing (RNA-Seq).

Region with largest share:

Because of the confluence of elements supporting greater investment, advances in technology, and scientific research, the Asia-Pacific area accounted for the largest proportion. Transcriptomic technologies are becoming more and more in demand as a result of the increased emphasis on genomics and precision medicine in nations like China, India, Japan, and South Korea. Additionally, the market is also expanding due to the availability of highly qualified researchers and rising awareness of the potential uses of transcriptomics in a variety of industries, such as environmental science, agriculture, and healthcare.

Region with highest CAGR:

Because of the growing investments in precision medicine, genomics, and joint research projects, the European region is predicted to have profitable growth. The adoption of advanced transcriptomic techniques and technical innovation have been facilitated by substantial support from academic institutions, research organizations, and government authorities. Moreover, transcriptomics is being actively used in drug discovery and development by the European biotechnology and pharmaceutical industries, which is fueling the market's growth in the region.

Key players in the market:

Some of the key players in Transcriptomics market include 10X Genomics, Agilent Technologies Inc., BGI Genomics, Bio-Rad Laboratories, Dovetail Genomics, F-Hoffmann La-Roche, Fluidigm Corporation, GE Healthcare Dharmacon Inc, General Electric Company, Illuminia Inc., Merck & Co. Inc, Natera Inc, Pacific Biosciences of California Inc., PerkinElmer Inc., Promega Corporation, QiagenInc Takara Bio Inc. and Thermofisher Scientific.

Key Developments:

In May 2022, BioSkryb Genomics launched the Early Access Program (EAP) for ResolveOME. This unified, single-cell workflow amplifies the complete genome and full-length mRNA transcripts of the entire transcriptome from the same cell.

In January 2022, Parse Biosciences, a provider of single-cell sequencing solutions for researchers partnered with Research Instruments Pte Ltd to provide Parse's Evercode Whole Transcriptome Kits (WTKs), Cell Fixation Kits, and Nuclei Fixation Kits in Singapore and Southeast Asia.

Components Covered:

  • Instruments
  • Services
  • Consumables
  • Software
  • Reagents
  • Other Components

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Microarrays
  • Real-time Quantitative Polymerase Chain Reaction (Q-PCR)
  • Sequencing Technology
  • Polymerase Chain Reaction (PCR)
  • Sanger
  • Other Technologies

Applications Covered:

  • Clinical Diagnostics
  • Drug Discovery
  • Diagnostics and Disease Profiling
  • Toxic genomics
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Government Institutes and Academic Centers
  • Contract Research Organizations
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Transcriptomics Market, By Component

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Services
  • 5.4 Consumables
  • 5.5 Software
  • 5.6 Reagents
  • 5.7 Other Components

6 Global Transcriptomics Market, By Technology

  • 6.1 Introduction
  • 6.2 Next-Generation Sequencing (NGS)
  • 6.3 Microarrays
  • 6.4 Real-time Quantitative Polymerase Chain Reaction (Q-PCR)
  • 6.5 Sequencing Technology
  • 6.6 Polymerase Chain Reaction (PCR)
  • 6.7 Sanger
  • 6.8 Other Technologies

7 Global Transcriptomics Market, By Application

  • 7.1 Introduction
  • 7.2 Clinical Diagnostics
  • 7.3 Drug Discovery
  • 7.4 Diagnostics and Disease Profiling
  • 7.5 Toxicogenomics
  • 7.6 Other Applications

8 Global Transcriptomics Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical and Biotechnology Companies
  • 8.3 Government Institutes and Academic Centers
  • 8.4 Contract Research Organizations
  • 8.5 Hospitals
  • 8.6 Other End Users

9 Global Transcriptomics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 10X Genomics
  • 11.2 Agilent Technologies Inc.
  • 11.3 BGI Genomics
  • 11.4 Bio-Rad Laboratories
  • 11.5 Dovetail Genomics
  • 11.6 F-Hoffmann La-Roche
  • 11.7 Fluidigm Corporation
  • 11.8 GE Healthcare Dharmacon Inc
  • 11.9 General Electric Company
  • 11.10 Illuminia Inc.
  • 11.11 Merck & Co. Inc
  • 11.12 Natera Inc
  • 11.13 Pacific Biosciences of California Inc.
  • 11.14 PerkinElmer Inc.
  • 11.15 Promega Corporation
  • 11.16 QiagenInc
  • 11.17 Takara Bio Inc.
  • 11.18 Thermofisher Scientific

List of Tables

  • Table 1 Global Transcriptomics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Transcriptomics Market Outlook, By Component (2021-2030) ($MN)
  • Table 3 Global Transcriptomics Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 4 Global Transcriptomics Market Outlook, By Services (2021-2030) ($MN)
  • Table 5 Global Transcriptomics Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 6 Global Transcriptomics Market Outlook, By Software (2021-2030) ($MN)
  • Table 7 Global Transcriptomics Market Outlook, By Reagents (2021-2030) ($MN)
  • Table 8 Global Transcriptomics Market Outlook, By Other Components (2021-2030) ($MN)
  • Table 9 Global Transcriptomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 10 Global Transcriptomics Market Outlook, By Next-Generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 11 Global Transcriptomics Market Outlook, By Microarrays (2021-2030) ($MN)
  • Table 12 Global Transcriptomics Market Outlook, By Real-time Quantitative Polymerase Chain Reaction (Q-PCR) (2021-2030) ($MN)
  • Table 13 Global Transcriptomics Market Outlook, By Sequencing Technology (2021-2030) ($MN)
  • Table 14 Global Transcriptomics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 15 Global Transcriptomics Market Outlook, By Sanger (2021-2030) ($MN)
  • Table 16 Global Transcriptomics Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 17 Global Transcriptomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 18 Global Transcriptomics Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 19 Global Transcriptomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 20 Global Transcriptomics Market Outlook, By Diagnostics and Disease Profiling (2021-2030) ($MN)
  • Table 21 Global Transcriptomics Market Outlook, By Toxicogenomics (2021-2030) ($MN)
  • Table 22 Global Transcriptomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 23 Global Transcriptomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 24 Global Transcriptomics Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 25 Global Transcriptomics Market Outlook, By Government Institutes and Academic Centers (2021-2030) ($MN)
  • Table 26 Global Transcriptomics Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 27 Global Transcriptomics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Transcriptomics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.